News

Get Alerts by Email

Sep 27, 2018

Galmed Pharmaceuticals to Present at the Cantor Global Healthcare Conference, ROTH Battle of the NASH Thrones Investor Conference and Stifel Healthcare Conference

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for...
- Photos 1
Aug 2, 2018

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2018 Financial Results

- Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST -

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, a...
- Photos 1
Jul 26, 2018

Galmed Pharmaceuticals to Report Second Quarter 2018 Financial Results and Provide Business Update on Thursday, August 2

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a...
- Photos 1
Jun 19, 2018

Galmed Pharmaceuticals Ltd. Announces Pricing of Public Offering of Ordinary Shares

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a...
- Photos 1
Jun 18, 2018

Galmed Pharmaceuticals Ltd. Announces Proposed Public Offering of Ordinary Shares

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a...
- Photos 1

Show per page